• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $JSPR

    Jasper Therapeutics Inc.

    Subscribe to $JSPR
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: jaspertherapeutics.com

    Peers

    $GRPH

    Recent Analyst Ratings for Jasper Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    2/13/2025$38.00Buy
    UBS
    12/6/2024$63.00Outperform
    BMO Capital Markets
    9/9/2024$70.00Mkt Outperform
    JMP Securities
    7/8/2024$90.00Buy
    BTIG Research
    6/27/2024$86.00Buy
    Stifel
    5/6/2024$65.00Buy
    H.C. Wainwright
    4/3/2024$65.00Outperform
    Evercore ISI
    3/28/2024$70.00Outperform
    RBC Capital Mkts
    3/18/2024Outperform
    TD Cowen
    8/11/2023$7.00Overweight
    CapitalOne
    See more ratings

    Jasper Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

      REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The BEACON update, based on a data-cut date of January 31, 2025, features approximately one month of additio

      3/1/25 12:45:13 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

      REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced a late-breaking oral presentation of briquilimab data from the Phase 1b/2a BEACON in CSU study at the 2025 AAD Annual Meeting, being held March 7 - 11, 2025, in Orlando, FL. The presentation will consist of data from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the BEACON study.

      2/28/25 8:00:59 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

      REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2024 and provided a corporate update. "The past year has been a transformational period for Jasper, highlighted by positive data readouts from the BEACON study in CSU and the SPOTLIGHT study in CIndU, our first two clinical studies evaluating Briquilimab in

      2/27/25 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics to Present at Upcoming March Investor Conferences

      REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Healthcare ConferenceConference Dates: March 3-5, 2025Presentation Date/Time: Monday, March 3, 2025; 1:20 p.m. ESTPresentation Format: Presentation Barclays 27th Annual Global Healthcare ConferenceConference Dat

      2/25/25 4:30:31 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

      REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced five poster presentations and an oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The oral presentation and one of the poster presentations will include additional follow-up from patients included in the Company's January 8th, 2025, discl

      2/10/25 8:00:56 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

      REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Oppenheimer Healthcare Life Sciences Conference, taking place February 11-12, 2025. Oppenheimer Healthcare Life Sciences ConferencePresentation Date/Time: Tuesday, February 11, 2025; 3:20 p.m. ESTPresentation Format: Fireside Chat A live webcast of the presentation will be ava

      2/4/25 4:30:35 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

      Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points 100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels Data supports commencement of CSU registrational program expected to commence second half of 2025 Company t

      1/8/25 7:00:37 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

      REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Jasper will host a virtual webinar on Wednesday, January 8, 2025, to present preliminary data from the BEACON study of briquilimab in CSU. In addition to management, the presentation will include remarks from Thomas B. Casale, M.D., Professor of Medicine and Pediatrics, University of South Florida Morsani College

      1/6/25 8:00:27 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

      REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the first patient has been dosed in Jasper's Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN (Evaluating The Efficacy and Safety of briquilimab In participANts with allergic asthma). The ETESIAN study is evaluating a single administration of subcutaneous briquilimab

      12/2/24 4:30:04 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics to Participate at Upcoming Investor Conferences

      REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences: Stifel 2024 Healthcare ConferenceConference Dates: November 18 – 19, 2024Presentation Date: Monday, November 18, 2024, 9:45 a.m. ETPresentation Format: Fireside Chat Jefferies London Healthcare Conference 2024Conference Dates: November 19-21, 2024 7th

      11/13/24 4:30:28 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Jasper Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Jasper Therapeutics with a new price target

      UBS initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $38.00

      2/13/25 8:09:46 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Jasper Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $63.00

      12/6/24 7:52:11 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Jasper Therapeutics with a new price target

      JMP Securities initiated coverage of Jasper Therapeutics with a rating of Mkt Outperform and set a new price target of $70.00

      9/9/24 7:39:14 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Jasper Therapeutics with a new price target

      BTIG Research initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $90.00

      7/8/24 8:07:11 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel initiated coverage on Jasper Therapeutics with a new price target

      Stifel initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $86.00

      6/27/24 7:47:49 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Jasper Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $65.00

      5/6/24 7:35:43 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Jasper Therapeutics with a new price target

      Evercore ISI initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $65.00

      4/3/24 7:46:58 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Jasper Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $70.00

      3/28/24 7:43:51 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Jasper Therapeutics

      TD Cowen initiated coverage of Jasper Therapeutics with a rating of Outperform

      3/18/24 8:14:51 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CapitalOne initiated coverage on Jasper Therapeutics with a new price target

      CapitalOne initiated coverage of Jasper Therapeutics with a rating of Overweight and set a new price target of $7.00

      8/11/23 9:34:25 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Jasper Therapeutics Inc. SEC Filings

    See more
    • SEC Form EFFECT filed by Jasper Therapeutics Inc.

      EFFECT - Jasper Therapeutics, Inc. (0001788028) (Filer)

      3/27/25 12:15:15 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Jasper Therapeutics Inc.

      424B5 - Jasper Therapeutics, Inc. (0001788028) (Filer)

      3/26/25 4:52:58 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      3/19/25 4:42:59 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Jasper Therapeutics Inc.

      S-3 - Jasper Therapeutics, Inc. (0001788028) (Filer)

      3/19/25 4:11:55 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Jasper Therapeutics Inc.

      10-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      2/28/25 9:20:43 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      2/27/25 8:05:10 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      1/8/25 7:05:29 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      11/7/24 7:42:21 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Jasper Therapeutics Inc.

      10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)

      11/7/24 7:30:40 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      10/15/24 6:03:19 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Jasper Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Jasper Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • SEC Form 4 filed by Chief Operating Officer Mahal Jeetinder Singh

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:31:26 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President, CEO and Director Martell Ron

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:30:52 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Cross Herb

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:30:21 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Tucker Edwin Jonathan

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:29:46 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Mahal Jeetinder Singh sold $19,899 worth of Voting Common Stock (900 units at $22.11) and exercised 900 units of Voting Common Stock at a strike of $7.10 (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      12/12/24 8:02:41 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Mahal Jeetinder Singh exercised 900 units of Voting Common Stock at a strike of $7.10 and sold $19,104 worth of Voting Common Stock (900 units at $21.23) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      9/12/24 5:19:07 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Lucas Svetlana

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      6/20/24 6:07:48 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Lucas Svetlana

      3 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      6/20/24 6:05:40 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Mahal Jeetinder Singh exercised 900 units of Voting Common Stock at a strike of $7.10 and sold $21,740 worth of Voting Common Stock (900 units at $24.16) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      6/12/24 9:40:02 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President, CEO and Director Martell Ron

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      6/12/24 4:09:26 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

      Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points 100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels Data supports commencement of CSU registrational program expected to commence second half of 2025 Company t

      1/8/25 7:00:37 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

      14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic induci

      10/14/24 7:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Jasper Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Carlyle Group Inc. bought $2,460,500 worth of Voting Common Stock (190,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/12/24 6:23:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Velan Capital Investment Management Lp bought $4,532,500 worth of shares (350,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/9/24 8:40:05 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiggans Thomas G bought $6,486 worth of Voting Common Stock (10,000 units at $0.65), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      11/30/23 4:05:16 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiggans Thomas G bought $18,240 worth of Voting Common Stock (30,000 units at $0.61) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      11/20/23 8:14:16 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Jasper Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/14/24 6:01:49 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/14/24 3:32:57 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/4/24 12:05:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Jasper Therapeutics Inc.

      SC 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

      3/27/24 4:26:42 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Jasper Therapeutics Inc. (Amendment)

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      2/14/24 6:18:35 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Jasper Therapeutics Inc. (Amendment)

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      2/14/24 4:18:20 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Jasper Therapeutics Inc. (Amendment)

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      2/14/24 9:41:13 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Jasper Therapeutics Inc. (Amendment)

      SC 13D/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      2/12/24 6:00:28 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Jasper Therapeutics Inc. (Amendment)

      SC 13D/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      2/9/24 8:36:52 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Jasper Therapeutics Inc. (Amendment)

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      2/5/24 9:15:02 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Jasper Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

      REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B

      6/19/24 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

      REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re

      11/1/23 8:00:00 AM ET
      $DERM
      $JSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Jasper Therapeutics Strengthens Management Team with Key Appointments

      Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations

      8/2/23 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

      Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

      6/20/23 8:00:00 AM ET
      $CABA
      $FBRX
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

      Accomplished Biotech and Large Pharma Executive to Lead Briquilimab Clinical Development Programs Daniel Adelman, M.D., Appointed to Scientific Advisory Board and as Senior Clinical Advisor REDWOOD CITY, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Edwin J. Tucker as Jasper's Chief Medical Officer. Concurr

      6/13/23 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board

      REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Stephen J. Galli, Professor of Pathology, Microbiology and Immunology, and the Mary Hewitt Loveless, M.D. Professor at Stanford Medicine, to the company's Scientific Advisory Board. "We are thrilled to welcome Dr. Galli to our Scientific Advisory Board," said Ron

      5/10/23 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations

      REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of David Hinds, as the Company's Senior Vice President, Development Operations. "We are pleased to welcome David to our team. His outstanding track record in setting strategic directions for clinical research and operations will allow us to effectively advance our dev

      4/10/23 4:05:00 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer

      REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Daniel Adelman, M.D., as the company's Acting Chief Medical Officer. Dr. Adelman is a highly experienced clinical leader and innovator and brings to Jasper more than 30 years of experience in the clinical development of novel therapies for immunologic diseases at Ai

      3/23/23 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update

      REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update. Highlights for Recent Weeks: Phase 1b data for JSP191 in the treatment of patients with MDS or AML accepted for presentation as a late breaking oral abstract at the Tandem Meetings of ASTCT and CIBMTR on April 26th, 2022. Data from 17 patients show JSP191, in combination with low dose radiation and fludarabine conditioning, was well tolerated in patients 62 to 79 years old with no JSP191-related se

      3/18/22 4:05:00 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer

      REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the appointment of Ronald Martell as the company's Chief Executive Officer effective March 15, 2022. "Ron is an experienced CEO with a proven track record of leading public biopharmaceutical companies in all phases of development, and we are pleased to welcome him as the Jasper CEO to lead the company through the next stage of growth and success," said Bill Lis, Chairman of Jasper Therapeutics. "Ron brings to Jasper a depth of experience in oncology and cell therapy development and commercialization, as

      2/28/22 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care